Bird&Be, a Toronto-based reproductive health company, raised a $13m Series A announced on 22 September 2026. BDC Capital's Thrive Fund and consumer-focused venture firm BFG Partners co-led the round.
BAM Ventures, Founder Collective, Rejuvenation Ventures and HSR Ventures also took part, according to law firm Osler, which advised on the deal. BetaKit reported that the round was all equity and equal to about C$18.3m.
Chief executive Samantha Diamond told BetaKit that the round closed in August and included a small amount of secondary shares. No valuation was disclosed.
What Bird&Be does
Bird&Be sells fertility and wellness supplements and at-home testing products for women and men. Its range is aimed at people trying to conceive, people who are pregnant and those recovering after birth, covering the stretch from prenatal care to postpartum.
The company's approach is to help customers spot possible fertility problems early with its test kits, then support their reproductive health with supplements from before conception through to recovery after birth.
Most customers buy on subscription. About 75% of the company's direct-to-consumer revenue comes from recurring orders, BetaKit reported. Bird&Be said all of its supplements are regulated by Health Canada under the country's natural health product rules.
The company offers reproductive health tests for both sexes. It cites studies showing that measures of male fertility have fallen significantly over the past 40 years as one reason for including men, rather than treating infertility as a women's issue only.
Founders and growth
Bird&Be was founded in 2019 by Breanna Hughes, who worked in tech, and Diamond, a former public relations specialist, according to BetaKit. Both founders have said they faced reproductive health problems themselves.
The company told BetaKit that it is profitable, describes itself as an eight-figure brand and has grown by nearly 100% year on year. It did not give exact revenue figures. Neither Osler nor BetaKit reported earlier funding rounds or a total amount raised.
BetaKit reported that Bird&Be sells its supplements and test kits mainly as subscriptions, with Diamond leading the company as chief executive.
What the money is for
Bird&Be plans to spend the money on product development and on widening retail distribution of its reproductive health products, Osler said.
The round pairs a government-backed investor with a consumer specialist. BetaKit identified the Thrive Fund as belonging to the Business Development Bank of Canada, and described BFG Partners as a consumer-focused venture firm.
A growing market for fertility products
Bird&Be points to the World Health Organization estimate that about one in six people experience infertility. BetaKit noted that infertility rates for men and women have risen worldwide over the past 30 years, as has the number of Canadians seeking fertility care.
Femtech has drawn growing interest from venture investors despite a long-standing funding gap. Within the category, companies focused on fertility and reproductive technology have raised the most money, BetaKit reported, citing Dealroom data.
Company website: birdandbe.com